LONDON (Reuters) – AstraZeneca is exploring its options for the future of its COVID-19 vaccine business and expects greater clarity on the matter by the end of 2021, a senior executive told Reuters on Thursday.
“We are exploring different options,” Ruud Dobber, executive vice president and president, BioPharmaceuticals Business Unit, told Reuters, referring to the vaccines business.
“Before year-end, we will have more clarity… if you ask me, is the vaccine businesses a sustainable business for AstraZeneca for the next five or 10 years, that big strategic question is under discussion.”
Source: Read Full Article
